The renal cell carcinoma market is witnessing a substantial change, largely fueled by label expansions of immune checkpoint inhibitor therapies. Combination regimens, including Opdivo plus Yervoy (Bristol Myers Squibb / Ono Pharmaceutical) and Keytruda (Merck & Co.) plus Inlyta (Pfizer), are revolutionizing the treatment of advanced disease. The approval and uptake of Opdivo plus Cabometyx (Exelixis / Ipsen) and Keytruda plus Lenvima / Kisplyx (Eisai) will also drive fierce competition in this setting. Treatment choices for early-stage disease are also increasing with Keytruda’s label expansion as an adjuvant therapy. Moreover, the FDA’s approval of Welireg (Merck & Co.) will reshape the treatment of VHL-associated tumors. The anticipated entry of other agents such as savolitinib (AstraZeneca) will further diversify treatment options during the forecast period and create a highly competitive and dynamic market.
What is the size of the early-stage and advanced / metastatic drug-treatable renal cell carcinoma population, and how will drug-treatment rates change over time?
What is the expected market impact of recent drug approvals and label expansions of novel combinations incorporating Opdivo, Cabometyx, Welireg, Lenvima / Kisplyx, and Keytruda for renal cell carcinoma?
Which are the most promising emerging therapies in the late-phase pipeline, and how will they shape the future of the renal cell carcinoma market?
What are the drivers and constraints in renal cell carcinoma, and how will the market evolve over the forecast period?
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.